Table 5.
Sorafenib plasma pharmacokinetic parameters in cancer patients with hepatic impairment
| Child-Pugh (CP) status | AUC0–8* (mg · h/L) | Cmax (mg/L) | tmax† (h) |
|---|---|---|---|
| CP A (n = 14) | |||
| Geometric mean | 25.4 | 4.9 | 1.0 |
| Approximate CV (%) | (38.4) | (38.7) | (0–12) |
| CP B (n = 8) | |||
| Geometric mean | 30.3 | 6.0 | 0.5 |
| Approximate CV (%) | (82.1) | (73.8) | (0–8) |
CV = coefficient of variation.
*
AUC0–8 was reported because plasma samples were collected only up to 8 hours in all patients.
†
Median (instead of geometric mean) and range (instead of approximate CV) are reported for tmax.